Radiation-Chemical Combo Enlists Killer T-Cells Against Lymphoma

Forever in search of a way to enlist the immune system to fight the growth of cancer in the body, researchers in England think they might have the latest answer.

University of Manchester researchers believe that a chemical known as R848 kick-starts immune cells by stimulating receptors on the cell surface. When researchers injected mice with R848, they saw an expansion in the blood of killer T-cells.

Radiation-chemical combo four times more effective

When they used R848 along with radiotherapy, they found that subjects (the mice) were four times more likely to experience long-term survival with lymphoma patients then if they received radiation therapy alone.

Their findings have been published in the journal of the American Society of Hematology, Blood.

Dr. Simon Dovedi of the University of Manchester's Institute of Cancer Sciences and Manchester Academic Health Science Centre commented:

"This could give patients a better response to conventional therapies through the generation of a lymphoma-specific immune response against tumor cells. This could be the key to ensuring long-term survival in more patients and reducing the number of relapses after initial therapy."

Very few side effects, long-term survival

Researchers saw little in the way of side effects or adverse events from R848 and radiotherapy. Every mouse with lymphoma treated with this combination experienced long-term survival, compared to a little more than one-quarter of the mice receiving radiotherapy alone.

Further, they believe that the activation of the immune system prevents cancer from recurrence.

Professor Chris Bunce of Leukemia & Lymphoma Research stated:

"These results are hugely promising. One of the major obstacles to long-term successful treatment for many types of lymphoma has been relapse after initial successful treatment. Treatment with R848 can prime T cells to recognize various tumor-associated antigens, protecting patients from the return of the cancer."

Source: MNT

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap